Comments
Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Bivalirudin injection. The approved ANDA is a generic equivalent to the reference listed drug (RLD) product Angiomax Injection of The Medicines Company.
Bivalirudin injection is indicated for use as an anti-coagulant in some patients. The estimated market size of the Bivalirudin injection is $101 million for the 12 months ending May 2018, according to IQVIA. The product will be launched in September 2018.
Aurobindo now has a total of 381 ANDA approvals (348 final approvals, including 17 from Aurolife Pharma LLC and 33 tentative approvals) from USFDA.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.